Ifw

DOCKET NO.: I0248.70015US01

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Bachovchin et al.

Serial No.:

10/725,952

Confirmation No.:

3968

Filed:

December 1, 2003

For:

STIMULATION OF HEMATOPOIETIC CELLS IN VITRO

Examiner:

Not Yet Assigned

Art Unit:

1631

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to MAIL STOP AMENDMENT, Commissioner for Patents, P.Q. Box 1450, Alexandria, VA 22313-1450, on

May 24, 2005.

Nicole Millette Hawes

# MAIL STOP AMENDMENT

Commissioner For Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Transmitted herewith are the following documents:

- Information Disclosure Statement
- PTO Form 1449
- Return Receipt Postcard

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 646-8000, Boston, Massachusetts.

A check is not enclosed. If a fee is required, the Commissioner is hereby authorized to charge Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.

Respectfully submitted,

Maria A. Trevisan, Reg. No.: 48,207 Wolf, Greenfield & Sacks, P.C.

600 Atlantic Avenue

Boston, Massachusetts 02210-2206

Telephone: (617) 646-8000

Docket No.: I0248.70015US01

Date: May 24, 2005

**xNDDx** 



DOCKET NO.: I0248.70015US01

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Bachovchin et al.

Serial No.:

10/725,952

Confirmation No.:

3968

Filed:

December 1, 2003

For:

STIMULATION OF HEMATOPOIETIC CELLS IN VITRO

Examiner:

Not Yet Assigned

Art Unit:

1631

#### **CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)**

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on May 24, 2005.

MAIL STOP AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

# STATEMENT FILED PURSUANT TO THE DUTY OF DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

# PART I: Compliance with 37 C.F.R. §1.97

This Information Disclosure Statement has been filed before the mailing date of a first Office Action on the merits in the above-identified case. No fee or certification is required.

### PART II: Information Cited

The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.

Serial No.: 10/725,952 -2 - Art Unit: 1631

Conf. No.: 3968

### PART III: Remarks

Documents cited anywhere in the Information Disclosure Statement are enclosed unless otherwise indicated. It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;

- 2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
- 3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his own conclusion regarding the relevance of the cited information.

An early and favorable action is hereby requested.

Respectfully submitted,

Maria A. Trevisan, Reg. No. 48,207

Wolf, Greenfield & Sacks, P.C.

600 Atlantic Avenue

Boston, Massachusetts 02210-2206

Telephone: (617) 646-8000

Docket No.: I0248.70015US01

Date: May 24, 2005

**xNDD**x

FORM PTO-1449/A and B (Modified)  INFORMATION DISCLOSURE STATEMENT BY APPLICANT  Sheet 1 of 1  Sheet 1 of 1  W.S. PATENT DOCUMENTS  Examiner's No. Number Kind Code No. Number Code No. Number Code No. Number					_					
FILING DATE: December 1, 2003   CONFIRMATION NO.: 3968	FOR A DTO	144044 1	D 44 1'C		APPLICATION NO.: 10/725,952		ATTY. DOCKET NO.: I0248.70015US01			
STATEMENT BY APPLICANT  Sheet 1 of 1  GROUP ART UNIT: 1631  EXAMINER: Not Yet Assign OPE  MAY 2.7 2002  MAY 2.7 2002  MAY 2.7 2002  WAY 2.7 2002  U.S. PATENT DOCUMENTS  U.S. PATENT DOCUMENTS  V.S. PATENT DOCUMENTS  Saminer's No.  FOREIGN PATENT DOCUMENTS  FOREIGN PATENT DOCUMENTS  Name of Patentee or Applicant of Cited Document MM-DD-YYYY  Name of Patentee or Applicant of Cited Document MM-DD-YYYY  Name of Patentee or Applicant of Cited Document (not necessary)  Translation (Y/N)  Office/ Country  Number  Skind Code  Office/ Country  Number  Name of Patentee or Applicant of Cited Document (not necessary)  Name of Patentee or Applicant of Cited Document (not necessary)  Name of Patentee or Applicant of Cited Document (N/N)  Office/ Country  Number  Name of Patentee or Applicant of Cited Document (not necessary)  Name of Patentee or Applicant of Cited Document (N/N)  Date of Publication of Cited Document (N/N)  Cite Document (N/N)  Translation (Y/N)  Date of Publication of Cited Document (N/N)  Cite Document (N/N)  Translation (Y/N)  Date of Publication of Cited Document (N/N)  Cite Document (N/N)  Date of Publication of Cited Document (N/N)  Cite Document (N/N)  Translation (Y/N)  Date of Publication of Cited Document (N/N)  Cite Document (N/N)  Cite Document (N/N)  Date of Publication of Cited Document (N/N)  Cite Document (N/N)  Cite Document (N/N)  Date of Publication of Cited Document (N/N)  Cite Document (N/N)	, ,				FILING DATE: December 1, 2003 CONFIRMATI			TON NO.: 3968		
Sheet   1   of   1     Of   1       Of   1       Of   1       Of   1     Of   1     Of   1     Of   1     Of   1     Of   1     Of   Of					APPLICANT: Bachovchin et al.					
Sheet   1   of   1     Of   1       Of   1       Of   1       Of   1     Of   1     Of   1     Of   1     Of   1     Of   1     Of   Of					GROUP	ART UNIT: 1631	EVAMINED	· Not Vet Assigne	MIP	E
Examiner's Initials    Cite   No.   Number   Kind   Code   Number   Code   Document   Name of Patentee or Applicant of Cited   Document   MM-DD-YYYY	Sheet	1	of	1	GROOF ART UNIT: 1031 EXAMINER: Not Yet Assi			Not let Assigne	u O	
Examiner's Initials    Cite   No.   Number   Kind   Code   Name of Patentee or Applicant of Cited   Document   MM-DD-YYYY									MAY 2 7	7 2005
Examiner's Initials  No. Number Kind Code  FOREIGN PATENT DOCUMENTS  Examiner's Initials  No. Office/ Country Number Kind Code  Office/ Country Number Kind Code  Office/ Code  Office/ Code  Office/ Code  Office/ Country Number Kind Code  Office/ Code  Offi		Г		S Patent Docume				Data of Publication	Ženia i	
FOREIGN PATENT DOCUMENTS    Cite   Foreign Patent Document   Name of Patentee or Applicant of Cited   Document   Cited Document   (not necessary)   Translation   Cited Document   (MM-DD-YYYY   MM-DD-YYYYY   MM-DD-YYYYY   MM-DD-YYYYY   MM-DD-YYYYY		1 [			Kind			of Cited Document		
Examiner's Initials    Cite   No.					Couc					
Examiner's Initials    Cite   No.	•				-		-			
Examiner's Initials    Cite   No.	÷	<u> </u>					- v			
Examiner's Initials    Cite   No.   Office/ Country   Number   Kind   Code   Number   Code   Code		<del></del> .						Data of		
Country Number Code (not necessary) Cite (MM-DD-YYYY MM-DD-YYYY MM-DD-YYYYY MM-DD-YYYYYY MM-DD-YYYYY MM-DD-YYYYYY MM-DD-YYYYYY MM-DD-YYYYY MM-DD-YYYYYY MM-DD-YYYYYY MM-DD-YYYYYY MM-DD-YYYYYYYYY MM-DD-YYYYYY MM-DD-YYYYYYYYYY					D		Publication of			
Examiner's Initials  Cite No  Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.  *C129  Darmoul et al., Dipeptidyl peptidase IV (CD 26) gene expression in enterocyte-like colon cancer cell lines HT-29 and Caco-2. Cloning of the complete human coding sequence and changes of dipeptidyl peptidase IV mRNA levels during cell differentiation. J Biol Chem. 1992 Mar 5; 267(7):4824-33.  *C130  Reinhold et al., Inhibitors of dipeptidyl peptidase IV (DP IV, CD26) specifically suppress proliferation and modulate cytokine production of strongly CD26 expressing U937 cells.				Number		(not necessary)	····		(Y/N)	
Examiner's Initials  Cite No  Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.  *C129  Darmoul et al., Dipeptidyl peptidase IV (CD 26) gene expression in enterocyte-like colon cancer cell lines HT-29 and Caco-2. Cloning of the complete human coding sequence and changes of dipeptidyl peptidase IV mRNA levels during cell differentiation. J Biol Chem. 1992 Mar 5; 267(7):4824-33.  *C130  Reinhold et al., Inhibitors of dipeptidyl peptidase IV (DP IV, CD26) specifically suppress proliferation and modulate cytokine production of strongly CD26 expressing U937 cells.		<del>                                     </del>								
Examiner's Initials  Cite No  Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.  *C129  Darmoul et al., Dipeptidyl peptidase IV (CD 26) gene expression in enterocyte-like colon cancer cell lines HT-29 and Caco-2. Cloning of the complete human coding sequence and changes of dipeptidyl peptidase IV mRNA levels during cell differentiation. J Biol Chem. 1992 Mar 5; 267(7):4824-33.  *C130  Reinhold et al., Inhibitors of dipeptidyl peptidase IV (DP IV, CD26) specifically suppress proliferation and modulate cytokine production of strongly CD26 expressing U937 cells.			-,			<del></del>	*****	~~~		
Examiner's Initials  Cite No  Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.  *C129  Darmoul et al., Dipeptidyl peptidase IV (CD 26) gene expression in enterocyte-like colon cancer cell lines HT-29 and Caco-2. Cloning of the complete human coding sequence and changes of dipeptidyl peptidase IV mRNA levels during cell differentiation. J Biol Chem. 1992 Mar 5; 267(7):4824-33.  *C130  Reinhold et al., Inhibitors of dipeptidyl peptidase IV (DP IV, CD26) specifically suppress proliferation and modulate cytokine production of strongly CD26 expressing U937 cells.	•			OTHER AL	PT NON	PATENT LITEDATUDE DOCU	IMENTS		I	
Initials  No  (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.  *C129  Darmoul et al., Dipeptidyl peptidase IV (CD 26) gene expression in enterocyte-like colon cancer cell lines HT-29 and Caco-2. Cloning of the complete human coding sequence and changes of dipeptidyl peptidase IV mRNA levels during cell differentiation. J Biol Chem. 1992 Mar 5; 267(7):4824-33.  *C130  Reinhold et al., Inhibitors of dipeptidyl peptidase IV (DP IV, CD26) specifically suppress proliferation and modulate cytokine production of strongly CD26 expressing U937 cells.	Examiner's	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item								tion
*C129 Darmoul et al., Dipeptidyl peptidase IV (CD 26) gene expression in enterocyte-like colon cancer cell lines HT-29 and Caco-2. Cloning of the complete human coding sequence and changes of dipeptidyl peptidase IV mRNA levels during cell differentiation. J Biol Chem. 1992 Mar 5; 267(7):4824-33.  *C130 Reinhold et al., Inhibitors of dipeptidyl peptidase IV (DP IV, CD26) specifically suppress proliferation and modulate cytokine production of strongly CD26 expressing U937 cells.			(book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s),							
dipeptidyl peptidase IV mRNA levels during cell differentiation. J Biol Chem. 1992 Mar 5; 267(7):4824-33.  *C130 Reinhold et al., Inhibitors of dipeptidyl peptidase IV (DP IV, CD26) specifically suppress proliferation and modulate cytokine production of strongly CD26 expressing U937 cells.		*C129	Darmoul	Darmoul et al., Dipeptidyl peptidase IV (CD 26) gene expression in enterocyte-like colon cancer						
*C130 Reinhold et al., Inhibitors of dipeptidyl peptidase IV (DP IV, CD26) specifically suppress proliferation and modulate cytokine production of strongly CD26 expressing U937 cells.										
proliferation and modulate cytokine production of strongly CD26 expressing U937 cells.			267(7):4824-33.							
		*C130	Reinhold et al., Inhibitors of dipeptidyl peptidase IV (DP IV, CD26) specifically suppress							
		1	<u> </u>		77.45.11				<u></u>	

EXAMINER:	DATE CONSIDERED:
The state of the s	

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

\*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. <u>09/812,528</u>, filed <u>March 20, 2001</u>, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - The Office hereby waives the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b). For all patent applications filed on or before June 30, 2003, copies of cited U.S. patents and patent application publications are still required unless an eIDS is filed. Copies of all other patent(s), publication(s), or other information listed must still be provided, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]